We are proud to share that our PI, Dr. Shin, has received the 25th Anniversary National Cancer Center President's Award.

This award stands as a testament to Dr. Shin’s enduring dedication to excellence in research and leadership. It is a deeply meaningful milestone that inspires our entire team as we continue to push the boundaries of science and innovation. Please join us in celebrating this wonderful honor and wishing Dr. Shin continued success!

We are excited to announce that our PI, Dr. Shin, together with co-investigator Dr. Kim Yun-hee, both of the National Cancer Center, has launched a new research project to develop a "Biological World Model" (BWM) — an AI framework designed to predict how candidate drugs will behave across different experimental systems, including cell lines, organoids, and animal models.

One of the greatest challenges in drug development is the "scale gap": compounds that perform well in cell-based experiments often fail to show the same effect in living systems, because complex biological features such as the tumor microenvironment, immune responses, and cell-to-cell interactions are not fully reproduced in the lab. As a result, enormous time and cost are invested, yet only a small fraction of candidates ultimately reach approval.

To bridge this gap, the team will treat cell lines, organoids, and animal models as distinct "biological worlds" and develop AI that can extend drug-response information learned in one system to another. Going beyond simply predicting whether a drug works, the model will leverage generative AI to forecast the intracellular changes a drug induces — including patterns of gene activation and suppression — effectively serving as a "virtual clinical trial" for drug candidates. The team also anticipates applications in precision medicine, where predicting patient-specific drug responses could support personalized treatment strategies for cancer patients.

This research is supported by the Ministry of Science and ICT's new "AI + Science & Technology (S&T) Innovation Technology Development" program (2026–2029, total funding of KRW 22.5 billion). Among six projects selected across major national strategic fields, the National Cancer Center's study was chosen as the representative project in the bio field, with KRW 3 billion in dedicated research funding.

We are proud to see Dr. Shin and Dr. Kim take on such a forward-looking challenge, and we look forward to sharing the team's progress as the project develops. Congratulations to Dr. Shin, Dr. Kim, and all collaborators on this exciting milestone!

ref : https://www.bosa.co.kr/news/articleView.html?idxno=3005661

https://www.newsmp.com/news/articleView.html?idxno=254208

https://www.medifonews.com/news/article.html?no=214091

https://www.etnews.com/20260604000067

https://www.mt.co.kr/amp/thebio/2026/06/04/2026060408415738800

Congratulations to our PI, Dr. Shin, and postdoctoral researcher Dr. Jonghyun Lee on being featured in the National Cancer Center Webzine (Fall 2025, Issue 3)!

The article highlights a collaborative study between the National Cancer Center and Seoul National University, which developed a novel morphology-based classification system for oral cancer using patient-derived organoids. This innovative approach enables prognosis prediction and personalized treatment strategies for oral cancer patients.

Dr. Lee contributed as a co-first author on this research, which was published in Cell Reports Medicine (IF 11.6) in May 2025. The study is recognized as the first in the world to quantitatively predict oral cancer prognosis and drug response by integrating organoid-based morphological classification with whole-genome/exome analysis.

We're proud to see our lab members' outstanding work featured in the National Cancer Center's official publication. Congratulations to Dr. Shin and Dr. Lee on this well-deserved recognition!

Congratulations to our PI, Dr. Shin, on being featured in the National Cancer Center Webzine (Fall 2025, Issue 3)!

The article highlights Dr. Shin's collaborative research with KAIST, which developed 'REVERT' — a systems biology-based platform that identifies molecular "reverse switches" capable of reverting cancer cells back to a near-normal state. This innovative approach opens new possibilities for cancer cell reprogramming therapies.

The study, published in Advanced Science (IF 14.1) in January 2025, demonstrates the potential of this technology using patient-derived colon cancer cell models.

We're proud to see Dr. Shin's pioneering work featured in the National Cancer Center's official publication. Congratulations on this well-deserved recognition!

Congratulations to our PI, Dr. Shin, on the media coverage of the groundbreaking cancer research published in Advanced Science!

The innovative 'REVERT' system developed by Dr. Shin's team in collaboration with KAIST has now been featured in a press release on BRIC, Korea's leading life science community platform. This research successfully identified genetic switches that can reverse cancer cell transformation - a major breakthrough in cancer biology.

We're proud to see Dr. Shin's exceptional work gaining well-deserved recognition in the scientific community. This media attention highlights the significant impact of our lab's contribution to understanding cancer progression mechanisms.

Congratulations, Dr. Shin, on this continued recognition of your outstanding research!

August 18th, 2025

Dr. Shin presented groundbreaking research at the 21st NCC Research Capsule, addressing the compelling question: "Can cancer cells be reverted to normal cells?" The presentation showcased our lab's innovative work on systematic biological technologies utilizing molecular dynamics for potential cancer cell normalization. Congratulations on this successful presentation to 99 attendees!

Dr. Jonghyun lee's paper has been published at Cell Reports Medicine in Cell Press. Congratulations on being registered in Hanbit-sa (Korea's Distinguished Scientists), honoring those who illuminate Korea with their exceptional achievements. Congratulations!

Dr. Bz lee's paper has been published at Briefings in Bioinformatics. Congratulations on being registered in Hanbit-sa (Korea's Distinguished Scientists), honoring those who illuminate Korea with their exceptional achievements. Congratulations!